A John Barrett

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. pmc CD34+ cells cultured in stem cell factor and interleukin-2 generate CD56+ cells with antiproliferative effects on tumor cell lines
    Giuseppe Sconocchia
    Hematology Branch, Stem Cell Allotransplantation Section, National Hearth Lung and Blood Institute, Bethesda, MD, USA
    J Transl Med 3:15. 2005
  2. pmc Relapse after allogeneic stem cell transplantation
    A John Barrett
    CRC Building 10 Room 3 5322, 10 Center Drive, MSC 1202, Bethesda, MD 20892 1202, USA
    Expert Rev Hematol 3:429-41. 2010
  3. ncbi request reprint Improving outcome of allogeneic stem cell transplantation by immunomodulation of the early post-transplant environment
    John Barrett
    Stem Cell Allotransplantation Section, Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Curr Opin Immunol 18:592-8. 2006
  4. pmc Does chemotherapy modify the immune surveillance of hematological malignancies?
    A J Barrett
    Stem Cell Allotransplantation Section, Hematology Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892 1202, USA
    Leukemia 23:53-8. 2009
  5. ncbi request reprint Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents
    A J Barrett
    Hematology Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda MD 20892 1202, USA
    Leukemia 20:1661-72. 2006
  6. doi request reprint Immunosuppressive therapy for myelodysplastic syndromes: refining the indications
    A John Barrett
    Clinical Research Center, National Heart, Lung, and Blood Institute, Bethesda, MD 20892, USA
    Curr Hematol Malig Rep 3:23-8. 2008
  7. doi request reprint Allogeneic stem cell transplantation for myelodysplastic syndrome
    A John Barrett
    Hematology Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Semin Hematol 45:49-59. 2008
  8. doi request reprint Understanding and harnessing the graft-versus-leukaemia effect
    A John Barrett
    Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892 1220, USA
    Br J Haematol 142:877-88. 2008
  9. pmc Translational mini-review series on vaccines: Peptide vaccines for myeloid leukaemias
    A J Barrett
    Stem Cell Allotransplantation Section, Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892 1202, USA
    Clin Exp Immunol 148:189-98. 2007
  10. ncbi request reprint T-cell depleted peripheral blood stem cell allotransplantation with T-cell add-back for patients with hematological malignancies: effect of chronic GVHD on outcome
    Aldemar Montero
    Stem Cell Allotransplantation Section, Hematology Branch, National Heart, Lung and Blood Institute, Bethesda, Maryland 20892 1202, USA
    Biol Blood Marrow Transplant 12:1318-25. 2006

Detail Information

Publications95

  1. pmc CD34+ cells cultured in stem cell factor and interleukin-2 generate CD56+ cells with antiproliferative effects on tumor cell lines
    Giuseppe Sconocchia
    Hematology Branch, Stem Cell Allotransplantation Section, National Hearth Lung and Blood Institute, Bethesda, MD, USA
    J Transl Med 3:15. 2005
    ..However, these CD56+ cells had the unusual property of inhibiting proliferation of K562 and P815 cell lines in a cell-contact dependent fashion...
  2. pmc Relapse after allogeneic stem cell transplantation
    A John Barrett
    CRC Building 10 Room 3 5322, 10 Center Drive, MSC 1202, Bethesda, MD 20892 1202, USA
    Expert Rev Hematol 3:429-41. 2010
    ..These features direct treatments toward either modified second transplants, chemotherapy, targeted antileukemia therapy, immunotherapy or palliative care...
  3. ncbi request reprint Improving outcome of allogeneic stem cell transplantation by immunomodulation of the early post-transplant environment
    John Barrett
    Stem Cell Allotransplantation Section, Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Curr Opin Immunol 18:592-8. 2006
    ..Many of these approaches appear feasible in clinical transplantation and have yielded promising initial results, but proof that the goal of controlled selective immune reconstitution can be achieved is still awaited...
  4. pmc Does chemotherapy modify the immune surveillance of hematological malignancies?
    A J Barrett
    Stem Cell Allotransplantation Section, Hematology Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892 1202, USA
    Leukemia 23:53-8. 2009
    ....
  5. ncbi request reprint Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents
    A J Barrett
    Hematology Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda MD 20892 1202, USA
    Leukemia 20:1661-72. 2006
    ..This review examines the origins of RIC SCT, explores the degree to which the initial expectations and purpose of the approach have been realized, and outlines some ways forward for the field...
  6. doi request reprint Immunosuppressive therapy for myelodysplastic syndromes: refining the indications
    A John Barrett
    Clinical Research Center, National Heart, Lung, and Blood Institute, Bethesda, MD 20892, USA
    Curr Hematol Malig Rep 3:23-8. 2008
    ..Significantly, long-term follow-up indicates that IST responders have a better progression-free survival than comparable patients with MDS who do not receive IST...
  7. doi request reprint Allogeneic stem cell transplantation for myelodysplastic syndrome
    A John Barrett
    Hematology Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Semin Hematol 45:49-59. 2008
    ....
  8. doi request reprint Understanding and harnessing the graft-versus-leukaemia effect
    A John Barrett
    Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892 1220, USA
    Br J Haematol 142:877-88. 2008
    ....
  9. pmc Translational mini-review series on vaccines: Peptide vaccines for myeloid leukaemias
    A J Barrett
    Stem Cell Allotransplantation Section, Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892 1202, USA
    Clin Exp Immunol 148:189-98. 2007
    ..These promising early results point the way to optimizing the administration of peptide vaccines and suggest ways of combining vaccination with allogeneic stem cell transplantation to boost GVL effects...
  10. ncbi request reprint T-cell depleted peripheral blood stem cell allotransplantation with T-cell add-back for patients with hematological malignancies: effect of chronic GVHD on outcome
    Aldemar Montero
    Stem Cell Allotransplantation Section, Hematology Branch, National Heart, Lung and Blood Institute, Bethesda, Maryland 20892 1202, USA
    Biol Blood Marrow Transplant 12:1318-25. 2006
    ..However, this chronic GVHD after T cell add back is associated with less mortality and retains a protective effect in terms of relapse, at least in the standard-risk patients...
  11. pmc Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia
    Katayoun Rezvani
    Stem Cell Allotransplantation Section, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892 1201, USA
    Blood 110:1924-32. 2007
    ..Our results support the immunogenicity of WT1 after SCT for ALL and highlight the potential for WT1 vaccines to boost GVL after SCT for ALL...
  12. pmc Chronic GVHD and pretransplantation abnormalities in pulmonary function are the main determinants predicting worsening pulmonary function in long-term survivors after stem cell transplantation
    Bipin N Savani
    Hematology Branch, National Heart, Lung and Blood, National Institutes of Health, Bethesda, Maryland 20892 1202, USA
    Biol Blood Marrow Transplant 12:1261-9. 2006
    ..Longer follow-up is needed to determine whether PF will continue to decrease or reach a plateau and whether more patients with PF abnormality will eventually become symptomatic...
  13. pmc Factors associated with early molecular remission after T cell-depleted allogeneic stem cell transplantation for chronic myelogenous leukemia
    Bipin N Savani
    Stem Cell Allogeneic Transplantation Section, Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bldg 10, Hatfield CRC, Bethesda, MD 20892 1202, USA
    Blood 107:1688-95. 2006
    ..These results suggest that transplanted CD34 cell doses greater than 5 x 10(6)/kg may improve outcomes by increasing the early recovery of NK cells...
  14. ncbi request reprint Lineage-specific engraftment and outcomes after T-cell-depleted peripheral blood stem cell transplant with Flu/Cy/TBI conditioning
    Aldemar Montero
    Stem Cell Allogeneic Transplantation Section, Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892 1202, USA
    Br J Haematol 130:733-9. 2005
    ..Early full T-cell engraftment correlated with development of severe acute graft-versus-host disease (GVHD). However, mixed T-cell chimaerism was favourable for reducing GVHD, and did not affect relapse in this small series...
  15. ncbi request reprint G-CSF-mobilized CD34+ cells cultured in interleukin-2 and stem cell factor generate a phenotypically novel monocyte
    Giuseppe Sconocchia
    Hematopoietic Stem Cell Transplantation Section, National Heart Lung and Blood Institute, National Institutes of Health, 9000 Rockville Pike, Bethesda MD 20892 0001, USA
    J Leukoc Biol 76:1214-9. 2004
    ..The generation of CD56+ cells was negatively regulated by hyaluronic acid and IL-4, indicating that extracellular matrix may play an important role in the commitment of CD34+ cells into CD56 myeloid and lymphoid lineages...
  16. pmc The transfer of adaptive immunity to CMV during hematopoietic stem cell transplantation is dependent on the specificity and phenotype of CMV-specific T cells in the donor
    Phillip Scheinberg
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA
    Blood 114:5071-80. 2009
    ....
  17. pmc In vitro induction of myeloid leukemia-specific CD4 and CD8 T cells by CD40 ligand-activated B cells gene modified to express primary granule proteins
    Hiroshi Fujiwara
    Stem Cell Allotransplant Section, Hematology Branch, National Heart, Lung, and Blood Institute, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 11:4495-503. 2005
    ..This study emphasizes the clinical potential of PGP for expansion and adoptive transfer of polyclonal leukemia antigen-specific T cells to treat leukemia...
  18. ncbi request reprint Persisting posttransplantation cytomegalovirus antigenemia correlates with poor lymphocyte proliferation to cytomegalovirus antigen and predicts for increased late relapse and treatment failure
    Ryotaro Nakamura
    Stem Cell Allogenetic Transplant Unit, Hematology Branch, National Heart, Lung and Blood Institute, Bethesda, Maryland 20892, USA
    Biol Blood Marrow Transplant 10:49-57. 2004
    ..The higher relapse rate may reflect poor immune reconstitution in ID patients or an adverse effect of prolonged antiviral treatment...
  19. pmc Reconstitution of FOXP3+ regulatory T cells (Tregs) after CD25-depleted allotransplantation in elderly patients and association with acute graft-versus-host disease
    Stephan Mielke
    Allotransplantation Section, Hematology Branch, National Heart, Lung, and Blood Institute NHLBI, National Institutes of Health NIH, Bethesda, MD 20892 1202, USA
    Blood 110:1689-97. 2007
    ....
  20. pmc Donor demographic and laboratory predictors of allogeneic peripheral blood stem cell mobilization in an ethnically diverse population
    Sumithira Vasu
    Department of Transfusion Medicine, Warren Grant Magnuson Clinical Center, National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 112:2092-100. 2008
    ..Age, white ethnicity, and female gender were associated with significantly lower post-G-CSF CD34(+) cell counts...
  21. ncbi request reprint Overcoming graft rejection in heavily transfused and allo-immunised patients with bone marrow failure syndromes using fludarabine-based haematopoietic cell transplantation
    Ramaprasad Srinivasan
    Urologic Oncology Branch, National Cancer Institute, Bethesda, MD, USA
    Br J Haematol 133:305-14. 2006
    ..These data show that HCT following fludarabine-based non-myeloablative conditioning results in durable engraftment and excellent survival in SAA and PNH patients at high risk for graft rejection...
  22. pmc Alloreactivity across HLA barriers is mediated by both naïve and antigen-experienced T cells
    J Joseph Melenhorst
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892 1202, USA
    Biol Blood Marrow Transplant 17:800-9. 2011
    ....
  23. pmc High avidity myeloid leukemia-associated antigen-specific CD8+ T cells preferentially reside in the bone marrow
    J Joseph Melenhorst
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 113:2238-44. 2009
    ..These data suggest that concomitant examination of bone marrow specimens in patients with myeloid leukemias might yield more definitive information in the search for immunologic prognosticators of clinical outcome...
  24. pmc Techniques to improve the direct ex vivo detection of low frequency antigen-specific CD8+ T cells with peptide-major histocompatibility complex class I tetramers
    Pratip K Chattopadhyay
    Immunotechnology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Cytometry A 73:1001-9. 2008
    ....
  25. ncbi request reprint Identification and in vitro expansion of CD4+ and CD8+ T cells specific for human neutrophil elastase
    Hiroshi Fujiwara
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 103:3076-83. 2004
    ..HNE could, therefore, be used in an HLA-unrestricted manner to induce leukemia-reactive CTLs for adoptive immunotherapy...
  26. pmc High PR3 or ELA2 expression by CD34+ cells in advanced-phase chronic myeloid leukemia is associated with improved outcome following allogeneic stem cell transplantation and may improve PR1 peptide-driven graft-versus-leukemia effects
    Agnes S M Yong
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892 1202, USA
    Blood 110:770-5. 2007
    ..The presence of a donor immune response against PR1 may be advantageous and could be exploited therapeutically...
  27. pmc Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome
    Elaine M Sloand
    Hematology Branch, National Heart, Lung, and Blood Institute, Bldg 10, Rm 7C108, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 106:841-51. 2005
    ..An increased number of T cells with apparent specificity for trisomy 8 cells is consistent with an autoimmune pathophysiology in trisomy 8 MDS...
  28. ncbi request reprint Gene therapy-based treatment for HIV-positive patients with malignancies
    Elizabeth M Kang
    Molecular and Clinical Hematology Branch, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD 20892, USA
    J Hematother Stem Cell Res 11:809-16. 2002
    ..Vector-transduced cells remain detectable at low levels more than 3 years post-transplantation, suggesting the potential for gene therapy as a reasonable goal for the treatment of HIV...
  29. pmc The clonal composition of human CD4+CD25+Foxp3+ cells determined by a comprehensive DNA-based multiplex PCR for TCRB gene rearrangements
    Phillip Scheinberg
    Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol Methods 321:107-20. 2007
    ..Clonotypes shared between the CD4+CD25+Foxp3+ and CD4+CD25+Foxp3- subsets were observed in all 3 UCB and in one adult PBMCs, suggesting that naïve and memory CD4+ T(R) can share the same clonotypes as CD4+ non-T(R) in humans...
  30. pmc Granulocyte colony-stimulating factor preferentially stimulates proliferation of monosomy 7 cells bearing the isoform IV receptor
    Elaine M Sloand
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 103:14483-8. 2006
    ..The abnormal response of monosomy 7 cells to GCSF would be explained by the expansion of undifferentiated monosomy 7 clones expressing the class IV GCSFR, which is defective in signaling cell maturation...
  31. pmc T-cell immune responses to Wilms tumor 1 protein in myelodysplasia responsive to immunosuppressive therapy
    Elaine M Sloand
    Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 117:2691-9. 2011
    ..Thus, our results suggest that WT1 is one of the antigens that triggers T cell-mediated myelosuppression in MDS...
  32. pmc Absolute lymphocyte count on day 30 is a surrogate for robust hematopoietic recovery and strongly predicts outcome after T cell-depleted allogeneic stem cell transplantation
    Bipin N Savani
    Hematology Branch, NHLBI, National Institutes of Health, Bethesda, Maryland 20892, USA
    Biol Blood Marrow Transplant 13:1216-23. 2007
    ..These results indicate that LC30 is a surrogate for robust engraftment and identifies an "at-risk" population of patients after T cell-depleted SCT...
  33. pmc The antileukemia effect of HLA-matched NK and NK-T cells in chronic myelogenous leukemia involves NKG2D-target-cell interactions
    Giuseppe Sconocchia
    Stem Cell Allotransplantation Section, Hematology Branch, National Heart Lung and Blood Institute, Department of Transfusion Medicine, Clinical Center, National Institutes of Health NIH, Bethesda, MD 20892, USA
    Blood 106:3666-72. 2005
    ..However, in vivo, CML cells may avoid NK-cell-mediated immune destruction by immune escape, shedding MICA into the plasma, thereby down-regulating NKG2D on CML CD56(+) cells...
  34. ncbi request reprint T-cell responses directed against multiple HLA-A*0201-restricted epitopes derived from Wilms' tumor 1 protein in patients with leukemia and healthy donors: identification, quantification, and characterization
    Katayoun Rezvani
    Stem Cell Allotransplantation Section, Hematology Branch, National Heart Lung Blood Institute and Vaccine Research Center, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 11:8799-807. 2005
    ..Four HLA-A*0201-restricted WT1-derived epitopes have been identified: WT37, WT126, WT187, and WT235. We determined the natural immunogenecity of these antigens in patients with hematologic malignancies and healthy donor...
  35. ncbi request reprint Improved outcome for peripheral blood stem cell transplantation for advanced primary myelodysplastic syndrome
    Scott R Solomon
    Stem Cell Allotransplantation Section, Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland 20892 1202, USA
    Biol Blood Marrow Transplant 11:619-26. 2005
    ..Although outcomes for all stages of primary MDS were improved, that for therapy-related MDS remained dismal, with 11% OS, because of a high relapse rate (89%)...
  36. pmc High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT
    Katayoun Rezvani
    Stem Cell Allogeneic Transplant Section, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892 1202, USA
    Blood 108:1291-7. 2006
    ..Our findings suggest that graft T(reg) content may predict for risk of GVHD after SCT. Determining the T(reg) levels in the donor and manipulating T(reg)s early after transplantation may provide a new approach to controlling GVHD...
  37. ncbi request reprint Unique abnormalities of CD4(+) and CD8(+) central memory cells associated with chronic graft-versus-host disease improve after extracorporeal photopheresis
    Kouhei Yamashita
    Laboratory of Host Defenses, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Biol Blood Marrow Transplant 12:22-30. 2006
    ..The contrasting change in central memory cells (CD8(+) increased versus CD4(+) decreased) in cGVHD provide support for recent reports suggesting unique differences in the differentiation pathways for CD8(+) versus CD4(+) T cells...
  38. pmc Donor KIR Genes 2DL5A, 2DS1 and 3DS1 are associated with a reduced rate of leukemia relapse after HLA-identical sibling stem cell transplantation for acute myeloid leukemia but not other hematologic malignancies
    Kate Stringaris
    Hematology Branch National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Biol Blood Marrow Transplant 16:1257-64. 2010
    ..These findings suggest specific, genetically determined, interactions between NK cells and AML cells that facilitate the GVL effect, and have implications for donor selection for AML patients...
  39. pmc Evolution of the donor T-cell repertoire in recipients in the second decade after allogeneic stem cell transplantation
    Robert Quan Le
    Stem Cell Allotransplantation Section, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA
    Blood 117:5250-6. 2011
    ..This study is registered at http://www.clinicaltrials.gov as NCT00106925...
  40. pmc A clinical-scale selective allodepletion approach for the treatment of HLA-mismatched and matched donor-recipient pairs using expanded T lymphocytes as antigen-presenting cells and a TH9402-based photodepletion technique
    Stephan Mielke
    Allotransplantation Section, Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892 1202, USA
    Blood 111:4392-402. 2008
    ..This procedure is currently being investigated in a clinical trial of allotransplantation...
  41. pmc Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation
    Scott R Solomon
    Stem Cell Allogeneic Transplantation Section, Hematology Branch, NHLBI, NIH Bldg 10, Hatfield CRC, Rm 3 5320, 10 Center Dr, MSC 1202, Bethesda, MD 20892 1202, USA
    Blood 106:1123-9. 2005
    ..Further studies with selectively depleted transplants to evaluate graft-versus-leukemia (GVL) and survival are warranted...
  42. pmc Rituximab administration within 6 months of T cell-depleted allogeneic SCT is associated with prolonged life-threatening cytopenias
    Zachariah McIver
    Stem Cell Allotransplantation Section, Hematology Branch, Heart Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Biol Blood Marrow Transplant 16:1549-56. 2010
    ..0 × 10⁹/L. Although RTX rapidly controlled cGVHD, we conclude that its administration early after T cell-deplete SCT is associated with prolonged profound and life-threatening cytopenias, and should be avoided...
  43. pmc Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib
    Agnes S M Yong
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892 1202, USA
    Blood 113:875-82. 2009
    ..Such treatment, as an adjunct to donor lymphocyte infusions and pharmacologic therapy, may reduce the risk of relapse in CML patients who require treatment by SCT...
  44. ncbi request reprint T-cell large granular lymphocyte leukemia is characterized by massive TCRBV-restricted clonal CD8 expansion and a generalized overexpression of the effector cell marker CD57
    J Joseph Melenhorst
    Stem Cell Allotransplantation Section, NHLBI, NIH, Bethesda, MD 20892, USA
    Hematol J 4:18-25. 2003
    ..We previously demonstrated that the clone can be found in both CD8+CD57+ and CD8+CD57- cells, indicating that the LGL clone also resides in the CD57- fraction...
  45. pmc Immune reconstitution in recipients of photodepleted HLA-identical sibling donor stem cell transplantations: T cell subset frequencies predict outcome
    Zachariah A Mciver
    Allotransplantation Section, Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Biol Blood Marrow Transplant 17:1846-54. 2011
    ....
  46. ncbi request reprint Early reconstitution of the T-cell repertoire after non-myeloablative peripheral blood stem cell transplantation is from post-thymic T-cell expansion and is unaffected by graft-versus-host disease or mixed chimaerism
    Erkut Bahceci
    Bone Marrow Transplant Unit, Hematology Branch, National Heart, Lung, and Blood Institute, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
    Br J Haematol 122:934-43. 2003
    ..These results define important qualitative differences in the T-cell repertoire according to the type of transplant schedule used...
  47. pmc Deficient CD4+ CD25+ FOXP3+ T regulatory cells in acquired aplastic anemia
    Elena E Solomou
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 110:1603-6. 2007
    ..Our findings indicate that decreased NFAT1 could explain low FOXP3 expression and diminished Treg frequency in aplastic anemia. Treg defects are now implicated in autoimmune marrow failure...
  48. pmc Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies
    Katayoun Rezvani
    Stem Cell Allotransplantation Section, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892 1201, USA
    Blood 111:236-42. 2008
    ..01). This is the first demonstration that a combined PR1 and WT1 vaccine is immunogenic. These results support further studies of combination immunization strategies in leukemia patients...
  49. ncbi request reprint Clonal dominance of chronic myelogenous leukemia is associated with diminished sensitivity to the antiproliferative effects of neutrophil elastase
    Frank El-Ouriaghli
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892, USA
    Blood 102:3786-92. 2003
    ..These results suggest that elastase overproduction by the leukemic clone can change the growth environment by digesting growth factors, thereby giving advantage to Ph+ hematopoiesis...
  50. pmc Increased risk of cervical dysplasia in long-term survivors of allogeneic stem cell transplantation--implications for screening and HPV vaccination
    Bipin N Savani
    Stem Cell Transplantation Section, Hematology Branch, NHLBI, National Institutes of Health, Bethesda, Maryland 20892 1202, USA
    Biol Blood Marrow Transplant 14:1072-5. 2008
    ..This may portend an increased risk of genital or other HPV-related malignancies...
  51. ncbi request reprint Alloreactive T cell clonotype recruitment in a mixed lymphocyte reaction: implications for graft engineering
    Phillip Scheinberg
    Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, MD 20892 1202, USA
    Exp Hematol 34:788-95. 2006
    ..To better understand the alloresponse between HLA-identical related pairs, we characterized the alloreactive T cells generated in a mixed lymphocyte reaction (MLR) assay system...
  52. ncbi request reprint HLA-DR4 predicts haematological response to cyclosporine in T-large granular lymphocyte lymphoproliferative disorders
    Minoo Battiwalla
    Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Br J Haematol 123:449-53. 2003
    ..We conclude that CSA is effective in inducing haematological responses in HLA-DR4-positive patients and that T-LGL is likely to have an immune pathogenesis...
  53. ncbi request reprint Contribution of TCR-beta locus and HLA to the shape of the mature human Vbeta repertoire
    J Joseph Melenhorst
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 180:6484-9. 2008
    ..We therefore conclude that the correlation in Vbeta expression patterns between CD4(+) and CD8(+) T cells can be explained predominantly by germline TCR-beta locus factors and not TCR-beta allelic or HLA effects...
  54. ncbi request reprint Engraftment syndrome after nonmyeloablative allogeneic hematopoietic stem cell transplantation: incidence and effects on survival
    Edward Gorak
    Walter Reed Army Medical Center, National Institutes of Health, Bethesda, Maryland 20892, USA
    Biol Blood Marrow Transplant 11:542-50. 2005
    ....
  55. ncbi request reprint Pediatric large-volume leukapheresis: a single institution experience with heparin versus citrate-based anticoagulant regimens
    Charles D Bolan
    Department of Transfusion Medicine, Warren G Magnuson Clinical Center, National Insitutes of Health, Bethesda, Maryland 20892 1184, USA
    Transfusion 44:229-38. 2004
    ..Anticoagulant-associated toxicity may exert significant effects on the safety and efficacy of large-volume leukapheresis (LVL) in children, however, few studies specifically address management of this issue...
  56. ncbi request reprint Efficacy of CD34+ stem cell dose in patients undergoing allogeneic peripheral blood stem cell transplantation after total body irradiation
    Anurag K Singh
    Radiation Oncology Branch, National Cancer Institute, Bethesda, Maryland 20892, USA
    Biol Blood Marrow Transplant 13:339-44. 2007
    ..A method for assessing risk of mortality by CD34(+) dose as a continuous variable is presented. Risk of mortality decreased with CD34(+) doses between 4-8 x 10(6) cells/kg and then began to increase...
  57. ncbi request reprint Prospective evaluation of cell kinetics, yields and donor experiences during a single large-volume apheresis versus two smaller volume consecutive day collections of allogeneic peripheral blood stem cells
    Charles D Bolan
    Department of Transfusion Medicine, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, MD, USA
    Br J Haematol 120:801-7. 2003
    ..This study indicates that a single 25-l apheresis procedure results in similar yields and symptoms, but less donor thrombocytopenia and inconvenience than two consecutive daily 15-l procedures...
  58. ncbi request reprint Prediction and prevention of transplant-related mortality from pulmonary causes after total body irradiation and allogeneic stem cell transplantation
    Bipin N Savani
    Stem Cell Allotransplant Section, Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA
    Biol Blood Marrow Transplant 11:223-30. 2005
    ..04), but lung shielding was not a significant independent factor for determining PTRM. These results suggest that pulmonary mortality after TBI-based preparative regimens is predictable and that higher CD34 cell doses can reduce the risk...
  59. ncbi request reprint Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation
    Katayoun Rezvani
    National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 102:2892-900. 2003
    ..The increased response in patients after SCT suggests a quantitative explanation for the greater effect of allogeneic SCT...
  60. pmc Long term maintenance of myeloid leukemic stem cells cultured with unrelated human mesenchymal stromal cells
    Sawa Ito
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA Electronic address
    Stem Cell Res 14:95-104. 2015
    ..We conclude that MSCs support long-term maintenance of LSCs in vitro. This simple and inexpensive approach will facilitate basic investigation of LSCs and enable screening of novel therapeutic agents targeting LSCs. ..
  61. doi request reprint Genetically engineered fixed K562 cells: potent "off-the-shelf" antigen-presenting cells for generating virus-specific T cells
    Kazushi Tanimoto
    Stem Cell Allogeneic Transplantation Section, Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA Electronic address
    Cytotherapy 16:135-46. 2014
    ..It is readily expandable, does not express human leukocyte antigen (HLA) class I and II and can be stably transduced with various genes...
  62. ncbi request reprint Treatment of relapsed blast-phase Philadelphia-chromosome-positive leukaemia after non-myeloablative stem-cell transplantation with donor lymphocytes and imatinib
    Bipin N Savani
    Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Building 10, Hatfield CRC, Room 3 5330, 10 Center Drive MSC 1202, Bethesda, MD 20892 1202, USA
    Lancet Oncol 6:809-12. 2005
  63. doi request reprint Allogeneic HLA-A*02-restricted WT1-specific T cells from mismatched donors are highly reactive but show off-target promiscuity
    Willem J J Falkenburg
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 187:2824-33. 2011
    ..As a result of this, administration of WT1-specific T cells generated from HLA-mismatched donors should be performed with appropriate precautions against potential off-target effects...
  64. pmc Immunomodulatory treatment of myelodysplastic syndromes: antithymocyte globulin, cyclosporine, and alemtuzumab
    Ankur R Parikh
    Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892 1202, USA
    Semin Hematol 49:304-11. 2012
    ....
  65. pmc Bone marrow homing and engraftment of human hematopoietic stem and progenitor cells is mediated by a polarized membrane domain
    Andre Larochelle
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA
    Blood 119:1848-55. 2012
    ....
  66. pmc Detection of low avidity CD8(+) T cell populations with coreceptor-enhanced peptide-major histocompatibility complex class I tetramers
    J Joseph Melenhorst
    Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol Methods 338:31-9. 2008
    ....
  67. ncbi request reprint Cytogenetic abnormalities in paroxysmal nocturnal haemoglobinuria usually occur in haematopoietic cells that are glycosylphosphatidylinositol-anchored protein (GPI-AP) positive
    Elaine M Sloand
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892 1652, USA
    Br J Haematol 123:173-6. 2003
    ..These findings suggest that environmental factors, but not genetic instability of the GPI-AP-deficient clone, foster development or survival of haematopoietic cells with chromosomal abnormalities...
  68. ncbi request reprint Severe chronic graft-versus-host disease is characterized by a preponderance of CD4(+) effector memory cells relative to central memory cells
    Kouhei Yamashita
    Laboratory of Host Defenses, National Institutes of Allergy and Infectious Diseases, National Institutes of Health NIH, Bethesda, MD 20892 1886, USA
    Blood 103:3986-8. 2004
    ..This finding implies that overrepresentation of CD4(EM) cells is a unique feature of cGVHD...
  69. pmc Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions
    Elaine M Sloand
    Hematology Branch, National Heart, Lung, and Blood Institute, Bldg 10 CRC 4 5230, Bethesda, MD 20892, USA
    J Clin Oncol 28:5166-73. 2010
    ..Because of the toxicities associated with h-ATG/CsA, we investigated an alternative regimen with alemtuzumab in MDS...
  70. ncbi request reprint Fas-mediated apoptosis is important in regulating cell replication and death in trisomy 8 hematopoietic cells but not in cells with other cytogenetic abnormalities
    Elaine M Sloand
    Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, MD 20892 1652, USA
    Blood 100:4427-32. 2002
    ..Clinical data demonstrating the responsiveness of some patients with trisomy 8 to anti-thymocyte globulin (ATG) and cyclosporine (CsA) would favor an active role of the immune system in this syndrome...
  71. ncbi request reprint Increased risk of bone loss without fracture risk in long-term survivors after allogeneic stem cell transplantation
    Bipin N Savani
    Stem Cell Allogeneic Transplantation Section, Hematology Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland 20892 1202, USA
    Biol Blood Marrow Transplant 13:517-20. 2007
    ..Our data shows that BL is a long-term posttransplant complication, and emphasize the importance of serial BMD scans, and the treatment of BL with biphosphonates reserved for worsening BL or additional risk factors...
  72. pmc Changes in salivary proteome following allogeneic hematopoietic stem cell transplantation
    Matin M Imanguli
    Clinical Research Core, National Institutes of Health, Bethesda, MD 20892, USA
    Exp Hematol 35:184-92. 2007
    ..This study was an initial evaluation of salivary protein changes that occur after allo-HCT...
  73. ncbi request reprint Nonmyeloablative conditioning followed by transplantation of genetically modified HLA-matched peripheral blood progenitor cells for hematologic malignancies in patients with acquired immunodeficiency syndrome
    Elizabeth M Kang
    Molecular and Clinical Hematology Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 99:698-701. 2002
    ..These results suggest that nonmyeloablative allogeneic transplantation in the context of highly active antiretroviral therapy is feasible in patients with treatment-sensitive HIV infection...
  74. pmc Prophylaxis of acute GVHD: manipulate the graft or the environment?
    A John Barrett
    Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA
    Best Pract Res Clin Haematol 21:165-76. 2008
    ....
  75. ncbi request reprint High-dose cyclophosphamide with autologous lymphocyte-depleted peripheral blood stem cell (PBSC) support for treatment of refractory chronic autoimmune thrombocytopenia
    Richard D Huhn
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA
    Blood 101:71-7. 2003
    ..This therapeutic approach is feasible for patients with severe chronic AITP, a substantial proportion of whom may obtain durable remissions. Larger controlled trials are recommended...
  76. ncbi request reprint Molecular and flow cytometric characterization of the CD4 and CD8 T-cell repertoire in patients with myelodysplastic syndrome
    J Joseph Melenhorst
    Hematology Branch, and Office of Biostatistics Research, NHLBI, NIH, Bethesda 20892, USA
    Br J Haematol 119:97-105. 2002
    ..Together, these data support the hypothesis of the involvement of T cells in the pathogenesis of MDS...
  77. pmc Function, adjustment, quality of life and symptoms (FAQS) in allogeneic hematopoietic stem cell transplantation (HSCT) survivors: a study protocol
    Margaret F Bevans
    National Institutes of Health Clinical Center, Bethesda, MD, USA
    Health Qual Life Outcomes 9:24. 2011
    ....
  78. ncbi request reprint Controlled study of citrate effects and response to i.v. calcium administration during allogeneic peripheral blood progenitor cell donation
    Charles D Bolan
    Department of Transfusion Medicine, Warren Grant Magnuson Clinical Center, Hematology Branch, National Heart, Lung and Blood Institute, NIH, Bethesda, MD 20892 1184, USA
    Transfusion 42:935-46. 2002
    ..However, neither the metabolic effects nor the management of associated symptoms have been critically evaluated during leukapheresis in healthy donors...
  79. ncbi request reprint Neutrophil elastase enzymatically antagonizes the in vitro action of G-CSF: implications for the regulation of granulopoiesis
    Frank El Ouriaghli
    Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 101:1752-8. 2003
    ..These results support a role for neutrophil elastase in providing negative feedback to granulopoiesis by direct antagonism of G-CSF...
  80. ncbi request reprint Pretransplant pulmonary function tests predict risk of mortality following fractionated total body irradiation and allogeneic peripheral blood stem cell transplant
    Anurag K Singh
    Radiation Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Int J Radiat Oncol Biol Phys 66:520-7. 2006
    ..To determine the value of pulmonary function tests (PFTs) done before peripheral blood stem cell transplant (PBSCT) in predicting mortality after total body irradiation (TBI) performed with or without dose reduction to the lung...
  81. pmc Pharmacokinetics of liposomal amphotericin B in pleural fluid
    Brad Moriyama
    NIH Clinical Center Pharmacy Department, 10 Center Drive, Bethesda, MD 20892, USA
    Antimicrob Agents Chemother 54:1633-5. 2010
    ..4%, with pleural fluid concentrations of 2.12 to 4.91 microg/ml. Given the relatively low level of intrapleural penetration of liposomal amphotericin B, chest tube drainage may be warranted for successful treatment of zygomycotic empyema...
  82. ncbi request reprint Clinical trial of quantitative real-time polymerase chain reaction for detection of cytomegalovirus in peripheral blood of allogeneic hematopoietic stem-cell transplant recipients
    Karoll J Cortez
    Clinical Mycology Section, Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    J Infect Dis 188:967-72. 2003
    ..Q-PCR was more sensitive than the antigenemia test and had sufficient specificity for clinical use...
  83. pmc Reactivation of hepatitis B with reappearance of hepatitis B surface antigen after chemotherapy and immunosuppression
    Tara N Palmore
    National Institute of Allergy and Infectious Diseases, National Institutes of Health, 10 Center Drive, MSC 1888, Bethesda, Maryland 20892 1888, USA
    Clin Gastroenterol Hepatol 7:1130-7. 2009
    ..We report 6 patients who experienced loss of serologic markers of hepatitis B immunity and reappearance of HBsAg in the serum as a result of a variety of acquired immune deficiencies...
  84. ncbi request reprint Differentiation of human bone marrow-derived cells into buccal epithelial cells in vivo: a molecular analytical study
    Simon D Tran
    National Institute of Dental and Craniofacial Research, Gene Therapy and Therapeutics Branch National Institutes of Health, Bethesda, MD 20892 1190, USA
    Lancet 361:1084-8. 2003
    ..We aimed to determine whether fusion events are important in vivo...
  85. ncbi request reprint Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes
    Jeffrey J Molldrem
    National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland 70892, USA
    Ann Intern Med 137:156-63. 2002
    ..Almost half of the deaths that result from myelodysplastic syndromes are due to cytopenia associated with bone marrow failure. Treatment is mostly supportive care...
  86. ncbi request reprint Recovery of spermatogenesis after total-body irradiation
    Bipin N Savani
    Blood 108:4292-3; author reply 4293-4. 2006
  87. ncbi request reprint Human leukocyte antigen (HLA) DR15 is associated with reduced incidence of acute GVHD in HLA-matched allogeneic transplantation but does not impact chronic GVHD incidence
    Minoo Battiwalla
    Department of Medicine and Laboratory Medicine, Blood and Marrow Transplantation, Roswell Park Cancer Institute, Buffalo, NY 14202, USA
    Blood 107:1970-3. 2006
    ..The HLA DR15-positive group experienced a significantly lower incidence of acute GVHD grades II to IV: 23% versus 42% (P = .041). These results suggest that HLA DR15 reduces the risk of acute GVHD...
  88. ncbi request reprint Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation
    John E Levine
    University of Michigan, Ann Arbor, MI, USA
    J Clin Oncol 20:405-12. 2002
    ..A chemotherapy strategy was used to debulk disease before administration of granulocyte colony-stimulating factor (G-CSF)-primed DLIs...
  89. ncbi request reprint Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse
    Stephanie J Lee
    Graft vs Host Disease Working Committee of the International Bone Marrow Transplant Registry, Health Policy Institute, Medical College of Wisconsin, Milwaukee, WI, USA
    Blood 100:406-14. 2002
    ..Survival and disease-free survival of the most favorable cGVHD group in each scheme were similar, or better, than those of patients without cGVHD; these patients may not need aggressive or extended immune suppression...
  90. pmc Impact of posttransplantation G-CSF on outcomes of allogeneic hematopoietic stem cell transplantation
    Hanna J Khoury
    Center for International Blood and Marrow Transplant Research CIBMTR, Health Policy Institute, Medical College of Wisconsin, Milwaukee, USA
    Blood 107:1712-6. 2006
    ..In conclusion, results of this study found no long-term benefit or disadvantage of giving G-CSF after transplantation to promote hematopoietic recovery...
  91. pmc Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems: a joint Société Française de Greffe de Moëlle et Thérapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR) pros
    Jean Yves Cahn
    Department of Onco Hematology, Hopital Michallon, Centre Hospitalo Universitaire, INSERM EMI 353, 38700 Grenoble Cedex 9, France
    Blood 106:1495-500. 2005
    ..Validity of these results in populations receiving peripheral blood transplants or nonmyeloablative conditioning regimens remains to be tested...
  92. ncbi request reprint Comparison of graft-versus-host-disease and survival after HLA-identical sibling bone marrow transplantation in ethnic populations
    Hakumei Oh
    GVHD Immune Reconstitution Wroking Committee of the International Bone Marrow Transplant Registry, Health Policy Institute, Medical College of Wisconsin, Milaukee, WI, USA
    Blood 105:1408-16. 2005
    ..04) and chronic (RR = 3.16; P = .002) GVHD. No differences in other clinical outcomes were noted. Our findings suggest that ethnicity may influence the risk for GVHD, though overall survival rates after transplantation remain similar...
  93. ncbi request reprint Decreased treatment failure in recipients of HLA-identical bone marrow or peripheral blood stem cell transplants with high CD34 cell doses
    Olle Ringden
    Division of Clinical Immunology F79, Huddinge University Hospital, S 141 86 Huddinge, Sweden
    Br J Haematol 121:874-85. 2003
    ..34, P = 0.003), lower risk of relapse (RR = 0.62, P = 0.029) and treatment failure (RR = 0.74, P = 0.03). We conclude that higher CD34 cell doses decrease treatment failure in recipients of HLA-identical sibling BM and PBSC transplants...
  94. ncbi request reprint Graft-versus-leukemia reactions in allogeneic chimeras
    Hans Jochem Kolb
    Hematopoietic Cell Transplantation, Dept of Medicine III, Clinical University of Munich Grosshadern, Marchioninistr 15, 81377 Munich, Germany
    Blood 103:767-76. 2004
    ..New approaches for adoptive immune therapy of leukemia, which promise a better prognosis for these patients, are being developed...
  95. pmc Characterizing and optimizing immune responses to leukaemia antigens after allogeneic stem cell transplantation
    Katayoun Rezvani
    Department of Haematology, 4th Floor Commonwealth Building, Hammersmith Hospital, DuCane Road, London W12 0NN, UK
    Best Pract Res Clin Haematol 21:437-53. 2008
    ..Finally, these approaches to increase GvL effects would be facilitated by transplant approaches to deplete GvHD alloresponses selectively while preserving GvL reactivity...